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Abstract: Background: The role played by vitamin D in atopic dermatitis is controversial and has been the focus 


































mainly in the skin when exposed to ultraviolet B 
(UVB).3 The biological actions of vitamin D have been 




diseases.4 In	 this	context,	 clinical	 trials	have	 failed	 to	
demonstrate a causal relationship.
Given the immunomodulatory role of vitamin 
D combined with its action in skin barrier formation 
and	recovery,	reducing	transepidermal	water	loss	and	
stimulating the production of antimicrobial peptides 
(AMP)	 by	 keratinocytes,	 macrophages,	 and	 neutro-
phils,	 it	 is	 reasonable	 to	 suppose	 that	 there	 is	 a	 link	
between the actions of vitamin D and the etiopatho-
genesis	 of	AD.3,5-9	 	 	However,	findings	 related	 to	 the	







confirmed	 in	 other	 studies.15-17	 Recently,	 clinical	 im-
provement of the disease after vitamin D supplemen-
tation has been demonstrated.16,18,19
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There is no consensus regarding optimal serum 
levels	of	25-hydroxy	vitamin	D	[25(OH)D],	the	metab-
olite used to determine the overall status of vitamin 
D,	or	the	time	of	its	storage	after	the	25-hydroxylation	




Ultraviolet	 (UV)	 radiation	 exerts	 immunosup-
pressive	 effects	 in	 AD	 patients	 and	 has	 been	 used	
successfully	 in	 the	 treatment	of	AD,	 in	methods	 like	
phototherapy or heliotherapy.21	 However,	 overexpo-
sure	 to	UV	 radiation	 from	 the	 sun	 and	 artificial	UV	
radiation	sources	is	a	public	health	concern.	UV	radi-
ation predisposes to skin cancer development and eye 
damage.	 In	 1995,	 in	 order	 to	 raise	 public	 awareness	
about	 the	excessive	exposure	 to	UV	and	 the	need	 to	
adopt	protective	measures,	the	World	Health	Organi-




UVI	 exposure	 categories:	 low,	 moderate,	 high,	 very	
high,	and	extreme.22,23	UVI	is	easily	obtained	from	me-
teorological	centers.	Nevertheless,	it	has	not	been	con-
sidered in research involving the association between 
AD	 and	 25(OH)D	 and	 its	 influence	 is	 unknown,	 as	
seen in the published results.
The	main	objectives	of	 the	present	study	were	







This cross-sectional study used a convenience 
sample of the pediatric dermatology outpatient clin-
ic	of	the	Hospital	Universitário	de	Brasilia,	located	in	
Brasilia,	Brazil	(latitude	15º46’	S,	longitude	47º55’	W).	
Data were collected by a single interviewer. The study 
was approved by the Research Ethics Committee at 




topical corticosteroids and oral antihistamines was 
allowed. Exclusion criteria were: systemic diseases; 
vitamin supplementation in the last 6 months; use of 
topical calcineurin inhibitors or oral corticosteroids 
in the past 4 weeks; phototherapy; use of anticonvul-
sants,	anticoagulants	or	antifungal	drugs;	and	derma-
toses or therapies that lead to reduced or increased 
sun exposure.
Inclusion criteria for the control group were age 
between	0	and	18	years	old	and	adequate	character-
istics for the matching criteria. The control group pa-
tients	were	matched	(1:1)	with	a	subsample	of	54	AD	
patients,	selected	according	to	the	chronological	order	
in which these patients entered the study. The con-




who met the same exclusion criteria as the cases and 
the	individuals	with	any	kind	of	atopy,	psoriasis,	and	
rosacea	were	 excluded.	 The	 patients	 of	 the	AD	 and	
control groups were selected from the same pediatric 
dermatology outpatient clinic.
The present study was conducted from Novem-
ber	 2012	 to	October	 2013.	AD	 severity	was	 assessed	
using	the	total	SCORing	Atopic	Dermatitis	(SCORAD)	
index.25 The	 following	 data	 were	 collected	 from	AD	
patients:	 age,	gender,	 skin	 type,	BMI,	other	personal	
atopy	 [asthma	 or	 allergic	 rhinitis	 (AR)],	 familial	 at-
opy,	age	of	onset	of	AD	symptoms,	SCORAD	index,	
25(OH)D,	 immunoglobulin	 E	 (IgE),	 complete	 blood	






D levels measured using the immuno-chemilumi-
nescence	method	 -	 LIAISON	XL	 platform	 (Diasorin,	
Sallugia,	 Italy).	The	25(OH)D	status	was	determined	
according to the reference values adopted by The 
Figure 1:	Inclusion	flowchart	(patients	with	AD	and	controls)
Endocrine Society.20 Total serum IgE was measured 
by immunonephelometry using the BN II and BN 
ProSpec	systems	(Siemens,	Marburg,	Germany).	Com-
plete blood counts were performed using Cell-Dyn 
Ruby	Abbott	 (Abbott	Laboratories,	Abbott	Park,	 Illi-
nois	USA),	and	the	stool	 tests	were	conducted	using	
the	 spontaneous	 sedimentation	 method.	 Local	 UVI	
was	obtained	daily	via	the	Brazilian	Center	for	Weath-
er Forecasting and Climate Studies site (available at 
http://satelite.cptec.inpe.br/uv/).	The	UVI	was	esti-
mated	 using	 a	 mathematical-physical	 model,	 which	
describes	transfer	of	UV	radiation	emitted	by	the	sun	
in the Earth’s atmosphere.
Data	were	 statistically	 analyzed	using	 SAS	 9.3	
(SAS	Institute,	Cary,	NC,	USA).	The	associations	includ-
ed	quantitative	and	qualitative	variables.	Associations	






of the matched groups. Multivariate analysis was per-
formed using multiple linear regression.
RESULTS





riod of completion of the study ranged from high to 
extreme	levels	(Figure	2).	The	stool	tests	did	not	detect	
presence of helminths.















Multiple linear regression analysis (r2	=	0.230)	showed	
that	IgE	and	UVI	were	predictors	significantly	associ-
ated	with	SCORAD	(β	=	0.002,	95%	CI	[0.001,	0.004],	p	
< 0.001 and β	=	-1.35,	95%	CI	[-2.357,	-0.352],	p	=	0.009,	
respectively).	The	associations	between	SCORAD	and	
the	other	variables	[age,	gender,	Fitzpatrick	skin	type,	
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level of 5.4 ng/ml higher than patients with skin type 
IV	and	V	(β	=	6.102,	95%	CI	[2.116,	10.088],	p	=	0.003).	
Older	 patients	 were	 associated	 with	 lower	 25(OH)










The prevalence of hypovitaminosis D was 
57.55%	in	the	AD	group.	This	prevalence	rate	is	sim-
ilar to that reported by Weng et al.26	 (55%)	 and	 Pe-
ters et al.27	 (60%)	in	adolescents.	This	prevalence	was	
higher	in	the	control	group,	affecting	77.78%	of	these	
patients. Such high prevalence rates are a reason for 
concern,	 since	 maximizing	 the	 peak	 of	 bone	 mass	
during adolescence and early adulthood is considered 
to be the best protection against age-related bone loss 
and late risk of osteoporosis.28 Although	this	study	was	
conducted	in	a	city	with	high	UVI,	ranging	from	high	
to	extreme,	 this	was	not	enough	 to	prevent	 the	high	
prevalence	 of	 25(OH)D	 insufficiency.	 Other	 authors	
have	also	found	low	levels	of	25(OH)D	in	healthy	in-
dividuals living in sunny regions.29
	We	demonstrated	 that	AD	 subgroup	patients	
had	 25(OH)D	 levels	 higher	 than	 matched	 controls.	
However,	25(OH)D	status	was	not	statistically	differ-
ent between the groups. Because small variations in 
the	serum	25(OH)D	level	may	not	be	clinically	signif-
icant,	 the	 association	 between	 categorical	 variables	
seems	to	be	more	appropriate.	Although	some	studies	
suggest a positive association between atopy and vita-
min	D,	we	believe	that	the	higher	level	of	25(OH)D	in	
AD	patients	is	linked	to	the	higher	UVI	in	this	group,	
as demonstrated by the paired analysis in our sample. 
14,30,31	We	found	no	statistically	significant	association	
between	 25(OH)D	 levels	 and	 AD	 clinical	 severity,	
which is in agreement with recent publications.16,17,32
In terms of independent variables associat-
ed	with	AD	severity,	 the	association	with	 IgE	 is	well	
known and has been reported by several other stud-







a	young	population	 is	not	 clear,	 although	 it	has	been	
previously reported.26 We agree with the authors who 
suggest that older children and adolescents may spend 
less time playing outdoors or may have a reduced oral 
supplementation of vitamin D.17,26 The reduction in the 
25(OH)D	levels	in	higher	skin	types	is	expected	because	
melanin	 competes	 for	UVB	photons.	Considering	 the	
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	 	 AD	subgroup		 Control	group
	 	 (n	=	54)	 (n	=	54)
Age	(years)	 9.1	±	4.1	 9.0	±	4.3
Gender
	 Male	 22	(40.74%)	 22	(40.74%)
	 Female	 32	(59.26%)	 32	(59.26%)
Fitzpatrick	skin	type
	 II	 1	(1.85%)	 5	(9.26%)
	 III	 17	(31.48%)	 9	(16.67%)
	 IV	 35	(64.82%)	 39	(72.22%)
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physiology	 of	 vitamin	D,	 the	 positive	 association	 be-
tween	UVI	and	25(OH)D	is	expected,	since	UVB	radi-
ation promotes the photolysis of 7-dehydrocholesterol 










verity	 and	 25(OH)D	 levels,	maybe	because	 the	 study	
was conducted in a very sunny city throughout the 
year,	 with	 low	 variation	 of	 its	 maximum	 UVI	 level.	
Most studies associate seasons to atopic diseases with-





ies. Silverberg et al. demonstrated lower prevalence of 
AD	in	U.S.	states	with	the	highest	UVI.38 The	same	way,	
studies	associate	UVI	to	other	diseases	(e.g.,	hay	fever	





advocate its use in research involving diseases that may 
be	influenced	by	UV	radiation,	such	as	AD	and	psori-













of	 cumulative	UV	 exposure,	 since	 its	 result	 is	 deter-
mined	 by	 the	 daily	 variations	 of	 UV	 exposure	 and	
by environmental conditions. The most widely used 
chemical dosimeters are polysulfone or polyphenylene 
oxide. Nowadays electronic devices are also available.
We considered a period of 30 days prior to clin-
ical	 evaluation	 to	 calculate	 mean	 UVI	 individually.	
However,	there	is	no	consensus	about	the	amount	of	UV	
exposure needed to maintain vitamin D levels. We es-
tablished	this	period	considering	the	half-life	of	25(OH)
D	(about	two	to	three	weeks),	the	related	improvement	
of	AD	 severity	 after	 4	 weeks	 of	 climatotherapy,	 and	
variation	of	 individual	habits	of	 sun	exposure,	 trying	
to reach intentional and non-intentional sun exposure 
periods.34,41	The	production	and	degradation	of	25(OH)
D is a continuous process. Establishing the ideal period 
to	measure	UV	effects	both	in	25(OH)D	production	and	
immunosuppression on an individual basis is a hard 




associated	with	 25(OH)D	 and	 SCORAD,	 the	 30	 days	
period may be a starting point to evaluate this issue.
This study was strictly controlled by the research-
ers,	thus	minimizing	measurement	biases.	All	tests	were	
performed	at	 the	same	 laboratories,	 therefore	ensuring	
technical uniformity. This strategy is of paramount im-
portance	for	the	measurement	of	25(OH)D	levels	because	
of the well-known inter assay variation.34 Our study lim-
















The role of vitamin D in atopic diseases is controver-
sial and continues to be investigated worldwide. The 
extent of its impact on the immune system and specif-
ically on allergic diseases has yet to be elucidated. We 
demonstrated	 the	 relevance	of	UVI	as	a	predictor	of	
25(OH)D	and	of	SCORAD,	even	 though	we	had	not	
considered	 solar	 exposure	 of	 participants.	 UVI	 can	
be easily obtained and should be included in studies 
involving	 25(OH)D	 and	 diseases	 influenced	 by	 UV	
because it may represent a confounding factor and 
distort	results.	The	use	of	UVI	individually	in	clinical	
research may shed some light and eliminate any shad-
ow	of	doubt	in	AD	and	vitamin	D	research.q
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